| Type 2 Diabetes Mellitus |
1 |
1 |
| Patient Safety |
0 |
0.77 |
| GLP-1 Receptor Agonist |
0 |
0.76 |
| Receptors |
0 |
0.59 |
| Weight Management |
0 |
0.59 |
| Adverse Effects |
0 |
0.47 |
| Weight Loss |
0 |
0.47 |
| Metabolic Syndrome |
0 |
0.39 |
| Biliary Disease |
0 |
0.28 |
| Non-Alcoholic Fatty Liver Disease |
0 |
0.28 |
| Fatty Liver |
0 |
0.17 |
| Hemoglobin A1c |
0 |
0.17 |
| Liver Disease |
0 |
0.17 |
| Social Determinants of Health |
0 |
0.15 |
| Europe |
0 |
0.12 |
| Health Care Quality, Access, and Evaluation |
0 |
0.12 |
| Hemoglobin |
0 |
0.12 |
| Hospital |
0 |
0.12 |
| Hypoglycemia |
0 |
0.12 |
| Liver |
0 |
0.12 |
| Metabolism |
0 |
0.12 |
| SGLT2 Inhibitor |
0 |
0.12 |